Abstract
Although there are multiple risk factors for obstructive sleep apnea, obesity is a significant actionable risk factor that is increasing worldwide. Studies have shown that weight loss whether through bariatric surgery or medications is associated with improvement in obstructive sleep apnea severity. This review summarizes the underlying mechanisms of glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptor agonists pertaining to weight loss and then summarizes the studies which show beneficial effects on weight loss in obese adults with or without diabetes. We then review the available studies showing a reduction in obstructive sleep apnea severity in adult patients with obesity primarily through weight reduction. Potential limitations and implications of treatment with these medications for obstructive sleep apnea will be reviewed.